Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Anaptysbio Inc (NQ: ANAB )

28.67 USD +0.36 (+1.27%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 15, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about Anaptysbio Inc

< Previous 1 2 Next >
AnaptysBio Reveals Updated Imsidolimab Data In Severe Form Of Psoriasis
AnaptysBio Inc(NASDAQ: ANAB) hasannounced updated datafrom the GALLOP Phase 2 trial of imsidolimab in generalized ... 
Tags Briefs Psoriasis Phase 2 Trial
From Benzinga
AnaptysBio to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
From GlobeNewswire News Releases
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ... 
Tags VIVE PHIO NBRV
From Benzinga
AnaptysBio-Generated Antibody Scores Second FDA Approval For Solid Tumor Indication
TheFDA has approved a second indicationforGlaxoSmithKline plc's(NYSE: GSK) Jemperli ... 
Tags Market News News Solid Tumor
From Benzinga
FDA Grants Accelerated Approval of JEMPERLI (dostarlimab-gxly) for dMMR Recurrent or Advanced Solid Tumors
From GlobeNewswire News Releases
AnaptysBio Announces Second Quarter 2021 Financial Results and Provides Pipeline Updates
From GlobeNewswire News Releases
AnaptysBio Breaks Below 200-Day Moving Average - Notable for ANAB
In trading on Monday, shares of AnaptysBio Inc (ANAB) crossed below their 200 day moving average of $24.77, changing hands as low as $24.06 per share. AnaptysBio Inc shares are currently trading off... 
Tags Stocks
From Market News Video
AnaptysBio to Present at the 2021 Jefferies Virtual Healthcare Conference
From GlobeNewswire News Releases
Benzinga's Top Ratings Upgrades, Downgrades For May 21, 2021
Upgrades According to JP Morgan, the prior rating for ResMed Inc (NYSE:RMD) was changed from Neutral to Overweight. For ... 
From Benzinga
The Past Week's Notable Insider Buys: Amphenol, Aldeyra, Werewolf Therapeutics, And More
Insider buying can be an encouraging signal for investors, especially when markets are near all-time highs. Some insiders have taken advantage of initial public offerings. A few chief executive... 
From TalkMarkets
The Past Week's Notable Insider Buys: Amphenol, Aldeyra, Werewolf Therapeutics And More
Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs. Once again, ... 
From Benzinga
AnaptysBio Announces First Quarter 2021 Financial Results and Provides Pipeline Updates
From GlobeNewswire News Releases
Last Week's Notable Insider Buys: Beacon Roofing, Chipotle, IPOs, Latham And More
Here are some of the most noteworthy insider purchases that were reported in the past week. 
From TalkMarkets
Last Week's Notable Insider Buys: Beacon Roofing, Chipotle, IPOs, Latham And More
Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs. Once again, ... 
From Benzinga
European Commission Approves JEMPERLI (dostarlimab), the First Anti-PD-1 Therapy Approved for Recurrent or Advanced dMMR/MSI-H Endometrial Cancer in Europe
From GlobeNewswire News Releases
FDA Approves JEMPERLI (dostarlimab-gxly) for dMMR Endometrial Cancer
From GlobeNewswire News Releases
AnaptysBio Announces Appointment of Oleg Nodelman to Board of Directors
From GlobeNewswire News Releases
AnaptysBio (ANAB) Shares Cross Above 200 DMA
In trading on Thursday, shares of AnaptysBio Inc (ANAB) crossed above their 200 day moving average of $22.44, changing hands as high as $22.66 per share. AnaptysBio Inc shares are currently trading up... 
From Market News Video
Interesting ANAB Put And Call Options For November 19th
Investors in AnaptysBio Inc (ANAB) saw new options become available this week, for the November 19th expiration. One of the key data points that goes into the price an option buyer is willing to pay,... 
From Market News Video
Why AnaptysBio Stock Is Attractive After 30% Selloff
AnaptysBio Inc’s (NASDAQ: ANAB) stock seems attractive after the POPLAR data and the 30% selloff, while there are several ... 
From Benzinga
Why AnaptysBio Stock Is Popping Today
This analyst is excited about the company's prospects. 
From Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For March 16, 2021
Upgrades Sidoti & Co. upgraded the previous rating for PAR Technology Corp (NYSE:PAR) from Neutral to Buy. For the ... 
From Benzinga
Why AnaptysBio Shares Rose Nearly 14% on Thursday
A phoenix may well rise from the ashes of a disappointing clinical trial. 
From Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For March 9, 2021
Upgrades ScotiaBank upgraded the previous rating for Primo Water Corp (NYSE:PRMW) from Sector Perform to Outperform. ... 
From Benzinga
66 Biggest Movers From Yesterday
Gainers Second Sight Medical Products, Inc. (NASDAQ: EYES) shares surged 103.3% to close at $11.77 on Monday on continued momentum ... 
From Benzinga
Why AnaptysBio Plummeted Today
The company's leading drug candidate failed to meet its primary endpoint in a phase 2 clinical trial. 
From Motley Fool
Noteworthy Monday Option Activity: ANAB, AERI, THC
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in AnaptysBio Inc (ANAB), where a total of 2,594 contracts have traded so far, representing... 
From Market News Video
Mid-Afternoon Market Update: Nasdaq Drops Over 150 Points; Crude Oil Down 2%
Toward the end of trading Monday, the Dow traded up 1.69% to 32,028.09 while the NASDAQ fell 1.23% to 12,761.08. The S&P also rose, ... 
From Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Second Sight Medical (NASDAQ:EYES) stock rose 96.45% to $11.38 during Monday's regular session. Second Sight ... 
From Benzinga
Dow, S&P 500 Jump Higher on Stimulus Progress
The Senate passed the $1.9 trillion Covid-19 relief bill on Saturday. 
From TalkMarkets
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.